Ozempic (semaglutide)

Yellow tape measure with a variety of weight loss medication on blue background
Biotech

Lilly's oral GLP-1 tied to 12% weight loss in phase 3 trial

Lilly is now headed toward regulators, angling to submit approval applications for the next-gen obesity asset by the end of 2025.
Gabrielle Masson Aug 7, 2025 6:30am
Doustdar
Favicon Fierce Pharma

Novo Nordisk names new CEO as it cuts sales, profit outlook

Jul 29, 2025 10:10am
Novo Nordisk CEO
Favicon Fierce Pharma

Novo's longtime CEO Lars Fruergaard Jørgensen to step down

May 16, 2025 9:41am
Eli Lilly

Lilly's oral GLP-1 delivers Ozempic-like efficacy in phase 3

Apr 17, 2025 6:45am
IPO art

Obesity biotech Metsera files for a swift IPO

Jan 11, 2025 9:05am
raised boxing glove with confetti falling around it

Chinese insulin maker’s GLP-1 bests Ozempic in ph. 2, company says

Oct 15, 2024 11:12am